Studi Literatur: Agen Antivirus pada Pasien COVID-19 dengan Penyakit Ginjal Kronis

Made Laksmi Meiliana, Didik Hasmono


At the end of 2019, Wuhan, Hubei Province, reported the first case of a virus similar to pneumonia. The World Health Organization (WHO) reports this outbreak as the Corona virus (COVID-19). Infection with COVID-19 may be more common in people who have chronic kidney disease (CKD). Patients with chronic kidney failure may experience infectious complications due to a weakened immune system and immunosuppressive state. Similarly, they suffer from a chronic systemic inflammatory state, which can contribute to increased morbidity and mortality. Thus, the purpose of this study is to conduct a review of antiviral agents and to summarize recommended antiviral regimens in COVID-19 patients with chronic kidney disease. This article search used Mendeley, Google Scholar, ScienceDirect, and PubMed from the NCBI database in October 2020. The administration of drugs to patients with chronic kidney disease who have been exposed to COVID-19 must be seriously considered. Certain antivirals must be adjusted to avoid deteriorating the patient's kidney condition. Antiviral agents are medications used to treat and prevent COVID-19 infection. Numerous antiviral agents, including ramdesivir, ribavirin, hydroxychloroquine or chloroquine, and umifenovir, must be administered with caution and dose adjustments as necessary in CKD patients exposed to COVID-19.

Save to Mendeley


COVID-19; chronic kidney disease; antiviral

Full Text:



Indra, S.(2020).Tinjauan Antivirus untuk Terapi COVID-19. CDK-286/ vol. 47,340-341

Jomah, S., Asdaq, SMB.,, Al-Yamani, MJ.(2020). Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. Elsevier 1187-1199.

Hassan. Kenar D. Perazella. (2020). COVID-19 therapeutic options for patients with kidney disease .Kidney International (2020) 97, 1297–1298;

Li, L., Wang, X., Wang, R., Hu, Y., Jiang, S., & Lu, X. (2020). Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. Drug Design, Development and Therapy, Volume 14, 3001–3013.


National Health Commission & State Administration of Traditional Chinese Medicine (Trial Version 7). Diagnosis and treatment protocol for novel coronavirus pneumonia. (

D’Marco, L., Puchades, M. J., Romero-Parra, M., Gimenez-Civera, E., Soler, M. J., Ortiz, A., & Gorriz, J. L. (2020). Coronavirus disease 2019 in chronic kidney disease. Clinical Kidney Journal.

Rudiansyah, M., Nur’amin, H., Lubis , Bandiara , Amirullah, RM., Roesli, Rachmadi, D.(2020). COVID-19 and Kidney Diseases in Indonesia. journal in the field of pharmacy. Sys Rev Pharm;11(7):435-442

Kidney Disease Improving Global Outcomes, KDIGO.(2012).Clinical Practice Guideline for the Evaluation and Management

Cohen G, Ho¨rl WH. Immune dysfunction in uremia:an update. Toxins 2012; 4: 962–990

Diao, B.; Feng, Z.; Wang, C.; Wang, H.; Liu, L.; Wang, C.; Wang, R.; Liu, Y.; Liu, Y.; Wang, G.; et al. Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. MedRxiv 2020, 2.

Gagliardi, I., Patella, G., Michael, A., Serra, R., Provenzano, M., & Andreucci, M. (2020). COVID-19 and the Kidney: From Epidemiology to Clinical Practice. Journal of Clinical Medicine.

Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020. doi:

Raza A, Estepa A, Chan V, Jafar MS. Acute Renal Failure in Critically Ill COVID-19 Patients With a Focus on the Role of Renal Replacement Therapy: A Review of What We Know So Far. Cureus. 2020;12(6). doi:10.7759/cureus.8429.

WHO. (2020). Coronavirus.

US Food and Drug Administration. Fact sheet for health care providers: Emergency use authorization (EUA) of Veklury® (remdesivir). Revised 2020 Aug. From FDA website. (

Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001; 285: 748–54.

Mitjà, O., Bonaventura Clotet.(2020). Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health,1-2.

Instiaty, Darmayani, I. G. A. A. P. S., Marzuki, J. E., Angelia, F., William, Siane, A., Sary, L. D., Yohanes, L., Widyastuti, R., Nova, R., Simorangkir, D. S., Lonah, Safitri, Y., Aliska, G., & Gayatri, A. (2020). Antiviral treatment of COVID-19: a clinical pharmacology narrative review. Medical Journal of Indonesia.

Izzedine, H., Jhaveri, K. D., & Perazella, M. A. (2020). COVID-19 therapeutic options for patients with kidney disease. In Kidney International.

K. Shiraki and T. Daikoku. (2020).Favipiravir, an anti-influenza drug against life-threatening RNA virus infections, Pharmacology &Therapeutics,

Khalili JS, Zhu H, Mak NSA, et al. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J Med Virol. 2020;92(7):740–746.

Merck & Co., Inc. Rebetol (ribavirin) package insert. Whitehouse Station, NJ: Merck & Co., Inc; 2013.

Adamsick, M. L., Gandhi, R. G., Bidell, M. R., Elshaboury, R. H., Bhattacharyya, R. P., Kim, A. Y., Nigwekar, S., Rhee, E. P., & Sise, M. E. (2020). Remdesivir in patients with acute or chronic kidney disease and COVID-19. In Journal of the American Society of Nephrology.

Grein, J., Ohmagari, N., Shin, D., Diaz, G., Asperges, E., Castagna, A., Feldt, T., Green, G., Green, M. L., Lescure, F. X., Nicastri, E., Oda, R., Yo, K., Quiros-Roldan, E., Studemeister, A., Redinski, J., Ahmed, S., Bernett, J., Chelliah, D., … Flanigan, T. (2020). Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine.

Vinetz JM. Chemotherapy of malaria. In: Brunton LL, Hilal- Dandan R, Knollmann BJ, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics 13th ed. New York: McGraw-Hill Education. 2018. p. 976–83.

Nugrahaningsih D, Eko Purnomo.(2020). Chloroquine and hydroxychloroquine for COVID-19 treatment. ournal of the Medical Sciences Volume 52, Number 3 (SI), 11-20

Ozyilmaz, E. (2020). Antiviral agents. Journal of Critical and Intensive Care.

Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol Pharmacol. 2014;86(6):665–74. doi: 10.1124/mol.11 4.094862

Binois, Yannick.(2020). Acute Kidney Injury Associated With Lopinavir/Ritonavir Combined Therapy in Patients With COVID-19. Kidney International Reports 5, 1777–1790

Sanofi-Aventis USLLC. Aralen (Chloroquine phosphate) package insert. Bridgewater, NJ: Sanofi-Aventis USLLC; 2017.

Barlow, A., Landolf, K. M., Barlow, B., Yeung, S. Y. A., Heavner, J. J., Claassen, C. W., & Heavner, M. S. (2020). Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. In Pharmacotherapy.

Acosta PE. Antiviral agents (nonretroviral). In: Brunton LL, Hilal-Dandan R, Knollmann BJ, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics 13th ed. New York: McGraw-Hill Education. 2018. p. 1105–16.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinicalcharacteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan,China: a descriptive study. Lancet (London, England) 2020;395(10223):507–13,